The Quantellect read.As of Nov 19, 2026, 10 active firms cover Oscar Health Inc: 3 rate it Buy or better, 6 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. Targets span $27.00 to $49.00, a moderate spread. The average target of $35.86 sits 30% above the current $27.57. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.27 next quarter toward $2.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Neutral
Strong Buy00%
Buy330%
Neutral660%
Sell110%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$35.86
+30.1% upside
Average target across 7 active firms as of Nov 19, 2026 vs $27.57 current
Highest Target$49.00
Average Target$35.86
Lowest Target$27.00
Detailed analyst forecasts for OSCR
Showing 1–8 of 8 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 3 of 10 active firms rate OSCR a Buy (6 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
OSCR EPS & revenue forecast
EPS · NEXT QUARTER
$2.27
Range $1.81 – $2.76 · 4 analysts · +9% YoY
Next period, 4 analysts expect Oscar Health Inc to earn $2.27 a share (range $1.81 – $2.76), versus $2.07 a year earlier. Full-year consensus is $2.37, growing to $2.45 the year after.
REVENUE · NEXT QUARTER
$5.5B
Range $5.0B – $5.8B · 4 analysts · +19% YoY
Revenue is expected to reach $5.5B (range $5.0B – $5.8B), +18.8% year-over-year. Full-year consensus is $19.1B, rising to $21.1B next year.
Top analysts covering Oscar Health Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OSCR.
#1
Stephen Baxter
Wells Fargo · Rank #63
Neutral
$27.00-2.1% to target
Overall win rate
47%
+ Follow
#2
Andrew Mok
Barclays · Rank #385
Buy
$49.00+77.7% to target
Overall win rate
39%
+ Follow
#3
JY
Jonathan Yong
UBS
Neutral
$36.00+30.6% to target
Coverage
—
+ Follow
#4
MH
Michael Ha
Baird
Neutral
$33.00+19.7% to target
Coverage
—
+ Follow
#5
AM
Andrew Mok CFA
Barclays
Buy
$49.00+77.7% to target
Coverage
—
+ Follow
OSCR stock forecast FAQ
What is OSCR's average 12-month price target?+
The 7 active firms with a live target average $35.86 for Oscar Health Inc over the next 12 months, ranging from a $49.00 high to a $27.00 low, as of Nov 19, 2026.
Is OSCR stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 10 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 6 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for OSCR?+
The Street-high target is $49.00 (Barclays), and the Street-low is $27.00 (Wells Fargo). The average of all 7 active-firm targets is $35.86.
How many active Wall Street firms cover OSCR?+
10 active firms have a recognized rating on Oscar Health Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering OSCR?+
Among analysts who currently cover OSCR, Stephen Baxter of Wells Fargo has the strongest overall Quantellect track record (Rank #63). Their current call is Neutral with a $27.00 target.
What is Oscar Health Inc's projected EPS for next quarter?+
The consensus estimate is $2.27 per share (range $1.81 – $2.76) across 4 analysts. Full-year EPS is projected at $2.37, rising to $2.45 the following year.
How much revenue is Oscar Health Inc expected to report next quarter?+
Consensus revenue is $5.5B (range $5.0B – $5.8B). Full-year revenue is projected at $19.1B, growing to $21.1B next year.
Have analysts been upgrading or downgrading OSCR lately?+
As of Nov 19, 2026, 3 of 10 active firms rate OSCR a Buy (6 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OSCR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.